Table 2.
Summary of HCV Vaccine Trials
| Mechanism | Phase 1‐4 | Status | Trial(s) |
|---|---|---|---|
| Neutralizing antibodies | Phase 1 | Completed | NCT00500747 |
| T cell–mediated immunity | Phase 1 | Active, not recruiting | NCT02362217 |
| NCT02568332 | |||
| T cell–mediated immunity | Phase 1/2 | Active, not recruiting or recruiting | NCT01436357 |
| NCT03119025 | |||
| T cell–mediated immunity | Phase 1 | Suspended | NCT02772003 |
| T cell–mediated immunity | Phase 1 | Completed | NCT01701336 |
| NCT00445419 | |||
| NCT01094873 | |||
| NCT01070407 | |||
| NCT01296451 | |||
| NCT00124215 | |||
| NCT02027116 | |||
| T cell–mediated immunity | Phase 2 | Completed | NCT00602784 |
| NCT01055821 | |||
| NCT00601770 | |||
| NCT00606086 |